Six MCL cell lines (Granta519, JVM2, Rec-1, Mino, Jeko-1 and Z-138) were characterized by WES to identify CARD11 mutations or related mutations and were also tested in vitro by treatment with ibrutinib (a BTK inhibitor) and/or lenalidomide (a NF-κB inhibitor). Here, BTK is linked to mantle cell lymphoma.